| Symbol | SNCG |
| Full Name | Gamma-Synuclein (Synoretin, BCSG1) |
| Chromosome | 10q23.2-q23.3 |
| NCBI Gene | 6623 |
| Ensembl | ENSG00000173267 |
| OMIM | 162267 |
| UniProt | P37841 |
| Protein Length | 127 amino acids (~14 kDa) |
| Gene Family | Synuclein (alpha, beta, gamma) |
| Associated Diseases | [Parkinson's Disease](/diseases/parkinsons-disease), [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies), [Multiple System Atrophy](/diseases/multiple-system-atrophy), [Alzheimer's Disease](/diseases/alzheimers-disease), Breast Cancer |
SNCG encodes gamma-synuclein (also known as synoretin or BCSG1), the third member of the synuclein family of proteins. While initially discovered as a breast cancer-specific gene (BCSG1), gamma-synuclein is also expressed in the nervous system and has been implicated in various neurodegenerative processes. Its role in neurodegeneration is less well-characterized than alpha-synuclein (SNCA) and beta-synuclein (SNCB), but emerging research suggests important functions in protein quality control and neuronal survival [1][2].
The synuclein family consists of three intrinsically disordered proteins that share structural features but have distinct expression patterns and biological functions [3][4]:
Gamma-synuclein shares structural features with other synucleins but has unique properties:
Gamma-synuclein is considered an intrinsically disordered protein, lacking fixed tertiary structure in solution. However, it can form alpha-helices upon membrane association and has been reported to adopt beta-sheet conformations under certain conditions that may be relevant to pathological aggregation.
One of the most significant functions of gamma-synuclein is its molecular chaperone properties [2:1][5]:
| Mechanism | Description | Evidence |
|---|---|---|
| Anti-Aggregation | Can inhibit alpha-synuclein fibrillization in vitro | Direct binding studies |
| Protein Quality Control | May function as a molecular chaperone | In vitro assays |
| Aggregate Clearance | Potential role in targeting misfolded proteins for degradation | Cell models |
| Oxidative Stress Protection | Protects against ROS-induced damage | Cell culture studies |
This chaperone activity positions SNCG as a potential modulator of alpha-synuclein pathology in synucleinopathies.
Within the nervous system, gamma-synuclein participates in multiple processes [6][7]:
Gamma-synuclein has significant functions outside the nervous system [1:1]:
| Tissue | Expression Level | Notes |
|---|---|---|
| Brain | Moderate | Cortex, hippocampus, cerebellum |
| Peripheral | High | Mammary gland, ovary, prostate |
| Cell-Type Specific | Moderate | Neurons and some glia |
| Serum | Low | Detectable, useful as biomarker |
Gamma-synuclein has several connections to Parkinson's disease [8][9][10][11]:
Expression Changes: Multiple studies have documented altered expression of gamma-synuclein in PD:
Aggregation: While gamma-synuclein does not form the extensive fibrillar inclusions that characterize alpha-synuclein pathology, it can form pathological inclusions under certain conditions and may co-aggregate with alpha-synuclein.
Interaction with α-Syn: Gamma-synuclein directly binds to alpha-synuclein and can modulate its aggregation dynamics:
Genetic Studies: SNCG variants may modify PD risk:
Neuroprotection: Some studies suggest protective effects against alpha-synuclein toxicity, possibly through chaperone activity that sequesters toxic alpha-synuclein species [2:2].
Neuroinflammation: Gamma-synuclein modulates microglial activation in PD models, suggesting a role in the neuroinflammatory component of PD [13].
Gamma-synuclein has significant relevance to dementia with Lewy bodies [14][10:1]:
Gamma-synuclein intersects with Alzheimer's disease pathology:
Recent research has identified connections between gamma-synuclein and TDP-43 pathology [15]:
Gamma-synuclein has significant cancer associations, originally discovered as a breast cancer biomarker (BCSG1) [1:2]:
| Cancer Type | Association | Clinical Relevance |
|---|---|---|
| Breast Cancer | Originally discovered as BCSG1 | Serum biomarker, associated with metastasis |
| Ovarian Cancer | Elevated expression | Prognostic marker |
| Prostate Cancer | High expression | Disease progression, castration resistance |
| Metastasis | Associated with metastasis | Poor prognosis marker |
The overexpression in cancer is thought to relate to its chaperone functions and effects on cell proliferation and survival.
| Partner | Interaction | Function |
|---|---|---|
| Alpha-Synuclein | Direct binding | Modulates aggregation |
| Beta-Synuclein | Heterodimer formation | Protective complexes |
| Tubulin | Microtubule binding | Cytoskeletal regulation |
| 14-3-3 Proteins | Chaperone interactions | Stress response |
| TDP-43 | Co-localization | RNA-protein homeostasis |
| Approach | Description | Status |
|---|---|---|
| Chaperone Enhancement | Small molecules enhancing gamma-synuclein function | Discovery |
| Aggregation Modulation | Targeting alpha-synuclein/gamma-synuclein interactions | Preclinical |
| Gene Therapy | Viral vector-mediated expression | Research |
| Protein-Based Therapy | Recombinant gamma-synuclein delivery | Preclinical |
The chaperone activity of gamma-synuclein makes it an attractive therapeutic target—it could potentially be harnessed to reduce toxic alpha-synuclein species.
Animal models have been useful for:
Ahmad M, Attoub S, Singh MN, et al. Gamma-synuclein and the progression of cancer. FASEB J. 2007. ↩︎ ↩︎ ↩︎
Liu HY, Chen WL, Sun HS. Gamma-synuclein is a novel neuronal protector against oxidative stress and mitochondrial dysfunction. J Neurochem. 2022. ↩︎ ↩︎ ↩︎
Spillantini MG, et al. Alpha-synuclein in Lewy bodies. Nature. 1997. ↩︎
Schneberger B, et al. Beta-synuclein: friend or foe in neurodegeneration?. J Neurochem. 2019. ↩︎
Kelley AR, et al. SNCG and protein quality control in neurodegeneration. Cell Mol Neurobiol. 2019. ↩︎
Tamo W, Mashima R, Saeki KD, et al. The distribution of gamma-synuclein in the mouse brain. Neuropathology. 2002. ↩︎
Nakai M, Maeda A, Mori M, et al. Gamma-synuclein modulates neuronal viability. J Neurosci Res. 2006. ↩︎
Park MJ, Cheon SM, Bae HR, et al. Elevated gamma-synuclein expression in Parkinson's disease. Mol Cells. 2011. ↩︎
Surguchov A. SNCG: the odd synuclein. Mov Disord. 2015. ↩︎
Bjorklund A, et al. Gamma-synuclein in Lewy body disease. Acta Neuropathol. 2019. ↩︎ ↩︎
Ishibashi T, et al. SNCG promoter variants and Parkinson's disease. Parkinsonism Relat Disord. 2019. ↩︎
Tong J, et al. SNCG in the olfactory system of PD patients. Mov Disord. 2019. ↩︎
Wang L, et al. SNCG and neuroinflammation in PD. J Neuroinflammation. 2021. ↩︎
Galvin JE, et al. SNCG expression in dementia with Lewy bodies. Neurology. 2020. ↩︎
Jin JK, Lee DB, Min DS, et al. Gamma-synuclein is upregulated in TDP-43 related neurodegenerative diseases. Acta Neuropathol Commun. 2023. ↩︎